ObjectiveTo provide a practical approach to pharmacists regarding the safe and effective use of nadofaragene firadenovec.Data sourcesClinical study data and pharmacist experience in institutional settings.Data summaryThis review article discusses the role of pharmacists caring for patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) receiving nadofaragene firadenovec. Pharmacist roles in a multidisciplinary care team are described and involve considerations surrounding nadofaragene firadenovec, including its mechanism of action, indication, handling, storage, administration, adverse event profile, disposal, counseling, and other practical points.ConclusionsPharmacists are positioned to be key contributors to the care team regarding the effective use of nadofaragene firadenovec. Further awareness and education will continue to optimize the clinical use of nadofaragene firadenovec in the high-risk BCG-unresponsive NMIBC setting.